Topical macrolide immunomodulators for therapy of atopic dermatitis

Atopic Dermatitis

Volumn , Issue , 2002, Pages 541-565

  Reitamo, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038595448     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. T Goto, T Kino, H Hatanaka, N Nishiyama, M Okuhara, M Kohsaka, H Aoki, H Imanaka. Discovery of FK-506, a novel immunosuppressant isolated from Strepto-myces tsukubaensis. Transpl Proc 19(suppl 6):4-8, 1987.
2. T Arai, Y Koyama, T Suenaga, H Honda. Ascomycin, an antifungal antibiotic. J Antibiot Ser A 15:231-232, 1962.
3. H Hatanaka, T Kino, S Miyata, N Inamura, A Kuroda, T Goto, H Tanaka, M Okuhara. FR-900520 and FR-900523, novel immunosuppressants isolated from a strep-tomyces II. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot 41:1592-1601, 1988.
4. H Nakagawa, T Etoh, Y Yokota, F Ikeda, K Hatano, N Teratani, K Shimomura, Y Mine, T Amaya. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patient with atopic dermatitis. Clin Drug Invest 12: 244-250, 1996.
5. M Grassberger, T Baumruker, A Enz, P Hiestand, T Hultsch, F Kalthoff, W Schuler, M Schulz, F-J Werner, A Winiski, B Wolff, G Zenke. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141:264-273, 1999.
6. MJ Tocci, DA Markovich, KA Collier, P Kwok, F Dumont, S Lin, S Degudicibus, JJ Siekierka, J Chin, NI Hutchinson. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143:718-726, 1989.
7. Thepen T, Langeveld-Wildschut EG, Bihari IC, van Wichen DF, van Reijsen FC, Mudde GC, Bruijnzeel-Koomen FM. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial Th2 response into a Th1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 97:828-837, 1996.
8. EA Wierenga, B Backx, M Snoek, L Koenderman, ML Kapsenberg. Relative contributions of human types 1 and 2 T-helper cell-derived eosinophilotrophic cytokines to development of eosinophilia. Blood 82:1471-1479, 1993.
9. A Wollenberg, S Kraft, D Hanau, T Bieber. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 106:446-453, 1996.
10. S Reitamo. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol 107:445-448, 2001.
11. A Panhans-Groβ, N Novak, S Kraft, T Bieber. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107:345-352, 2001.
12. A Wollenberg, S Sharma, D von Bubnoff, E Geiger, J Haberstok, T Bieber. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107:519-525, 2001.
13. A De Paulis, C Stellato, R Cirillo, A Ciccarelli, A Oriente, G Marone. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99:723-728, 1992.
14. A De Paulis, R Cirillo, A Ciccarelli, M Condorelli, G Marone. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human FceRI + cells. J Immunol 146:2374-2381, 1991.
15. SM Hatfield, NW Roehm. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther 260:680-688, 1992.
16. SM Hatfield, JS Mynderse, NW Roehm. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. J Pharmacol Exp Ther 261:970-976, 1992.
17. T Hultsch, KD Mueller, JG Meingassner, M Grassberger, RE Schopf, J Knop. As-comycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesised cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 290:501-507, 1998.
18. T Zuberbier, S Chong, S Guhl, P Welker, BM Henz, M Grassberger. SDZ ASM 981 inhibits anti-IgE stimulated mediator release in human dermal mast cells (abstr). J Invest Dermatol 112:608, 1999.
19. T Sengoku, K Morita, S Sato, S Sakuma, T Ogawa, J Hiroi, T Fujii, T Goto. Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice. Nippon Yakarigaku Zasshi 112:221-232, 1998.
20. T Sengoku, K Morita, S Sakuma, Y Motoyama, T Goto. Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models. Eur J Pharmacol 379:183-189, 1999.
21. AB Kay, S Ying, V Varney, M Gaga, SR Durham, R Moqbel, et al. Messenger RNA expression of cytokine gene cluster, interleukin 3 (IL-3), IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 173:775-778, 1991.
22. JG Meingassner, A Stütz. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98: 851-855, 1992.
23. AI Lauerma, HI Maibach, H Granlund, P Erkko, M Kartamaa, S Stubb. Inhibition of contact allergy reaction by topical FK 506 (letter). Lancet 340:556, 1992.
24. JG Meingassner, M Grassberger, H Fahrngruber, HD Moore, H Schuurman, A Stutz. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137:568-576, 1997.
25. D Bochelen, M Rudin, A Sauter. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 288:653-659, 1999.
26. th Congress of the European Academy of Dermatology and Venereology, October 11-15, 2000, Geneva, Switzerland.
27. J Hiroi, T Sengoku, K Morita, S Kishi, S Sato, T Ogawa, M Tsudzuki, H Matsuda, A Wada, K Esaka. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 76:175-183, 1998.
28. G Neckermann, A Bavandi, J Meingassner. Atopic dermatitis-like symptoms in hy-pomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol. 142:669-679, 2000.
29. H Jiang, S Sakuma, Y Fujii, Y Akizama, T Ogawa, K Tamura, M Kobayashi, T Fujitsu. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. Transpl Int 12:92-99, 1999.
30. N Murase, AJ Demetris, J Woo, M Tanabe, T Furaya, S Todo, TE Starzl. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-brown Norway rat intestinal transplantation under FK506. Transplantation 58:1-7, 1993.
31. A Hisatomi, T Mitamura, M Kimura, Y Oishi, T Fujii, K Ohara. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal atrophogenicity in rats. J Toxicol Pathol 10:97-102, 1997.
32. S Reitamo, J Rissanen, A Remitz, H Granlund, P Erkko, P Elg, P Autio, AI Lauerma. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111:396-398, 1998.
33. JP Ortonne. SDZ ASM 981 does not induce skin atrophy: a randomised, doubleblind controlled study (abstr). J Eur Acad Dermatol Venereol 12(suppl 2):S140, 1999.
34. C Queille-Roussel, C Paul, L Duteil, MC Lefebvre, G Raptz, M Zagula, JP Ortonne. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: a randomised, double-blind controlled study. Br J Dermatol 144:507-513, 2001.
35. S Alaiti, S Kang, VC Fiedler, CN Ellis, DV Spurlin, D Fader, G Ulyanov, SD Gadgil, A Tanase, I Lawrence, P Scotellaro, K Raye, I Bekersky. Tacrolimus (FK506) 0.3% ointment for atopic dermatitis; a phase I study in adults and children. J Am Acad Dermatol 38:69-76, 1998.
36. M Kawashima, H Nakagawa, M Ohtsuji, K Tamaki, Y Ishibashi. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis (letter). Lancet 348: 1240-1241, 1996.
37. M Graeber, EJM Van Leent, P Burtin, ME Ebelin, B Dorobek, JD Bos. Profiling SDZ ASM 981: evaluation of local tolerability and safety in the treatment of atopic dermatitis (abstr). Ann Dermatol Venereol 125(suppl 1):214-215, 1998.
38. th Congress of the European Academy of Dermatology and Venereology, October 11-15, 2000, Geneva, Switzerland.
39. th Annual Meeting of the American Academy of Dermatology, March 2-7, 2001, Washington, DC.
40. th Congress of the European Academy of Dermatology and Venereology, October 11-15, 2000, Geneva, Switzerland.
41. JD Bos, MMHM Meinardi. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9:165-169, 2000.
42. Y de Prost, C Bodemer, D Teillac. Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis. Arch Dermatol 125:570, 1989.
43. MA de Rie, MMHM Meinardi, JD Bos. Lack of efficacy of topical cyclosporin in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 71:452-454, 1991.
44. H Nakagawa, T Etoh, Y Ishibashi, Y Higaki, M Kawashima, H Torii, S Harada. Tacrolimus ointment for atopic dermatitis (letter). Lancet 344:883, 1994.
45. H Aoyama, N Tabata, M Tanaka, Y Uesugi, H Tagami. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment (letter). Br J Dermatol 133:494-496, 1995.
46. T Ruzicka, T Bieber, E Schöpf, A Rubins, A Dobozy, JD Bos, S Jablonska, I Ahmed, K Thestrup-Pedersen, F Daniel, A Finzi, S Reitamo. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337:816-821, 1997.
47. JM Hanifin, MR Ling, R Langley, D Breneman, E Rafal and the Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy. J Am Acad Dermatol 44:S28-S38, 2001.
48. NA Soter, AB Fleischer, GF Webster, E Monroe, I Lawrence and the Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. J Am Acad Dermatol 44:S39-S46, 2001.
49. S Reitamo, A Wollenberg, E Schöpf, JL Perrot, R Marks, T Ruzicka, E Christophers, A Kapp, M Lahfa, A Rubins, S Jablonska, M Rustin. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 136:999-1006, 2000.
50. R Aly. Bacteriology of atopic dermatitis. Acta Dermatol Venereol 92:16-18, 1980.
51. A Remitz, H Kyllonen, H Granlund, S Reitamo. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions (letter). J Allergy Clin Immunol 107:196-197, 2001.
52. T Kino, H Hatanaka, M Hashimoto, M Nishiyama, T Goto, M Okuhara, M Kohsaka, H Aoki, T Ochiai. FK 506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physio-chemical and biological characteristics. J Anti-biot (Tokyo) 49:1249-1255, 1987.
53. EJM Van Leent, M Gräber, M Thurston, A Wagenaar, PI Spuls, J Bos. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 134:805-809, 1998.
54. T Luger, EJM van Leent, M Graeber, S Hedgecock, M Thurston, A Kandra, J Berth-Jones, J Bjerke, E Christophers, J Knop, AC Knulst, M Morren, A Morris, S Rei-tamo, J Roed-Petersen, E Schoepf, K Thestrup-Pedersen, PGM van der Valk, JD Bos. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 144:788-794, 2001.
55. EJM Van Leent, M Graeber, ME Ebelin, P Burtin, HJC de Vries, JD Bos. Efficacy and safety of SDZ ASM 981 cream in atopic dermatitis (abstr). J Eur Acad Dermatol Venereol 12:51, 1999.
56. M Graeber, EJM van Leent, M Thurston, JD Bos. SDZ ASM 981 cream: an emerging new drug for treatment of atopic dermatitis. Poster presented at the Clinical Dermatology 2000 Congress, June 18-20, 1998, Singapore.
57. JD Bos, K Meyer, HJC de Vries, S Molloy, A Kandra, M Graeber on behalf of the European/Canadian Study Group. Long-term safety and efficacy of SDZ ASM 981 cream in adult patients with atopic dermatitis (abstr). Br J Dermatol 143:S34, 2000.
58. M Boguniewicz, VC Fiedler, S Raimer, ID Lawrence, DYM Leung, JN Hanifin for the Pediatric Tacrolimus Study Group. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 102:637-644, 1998.
59. A Paller, LF Eichenfield, DYM Leung, D Steward, M Appell and the Tacrolimus Ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44:S47-S57, 2001.
60. S Kang, AW Lucky, D Pariser, I Lawrence, JM Hanifin and the Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 44:S58-S64, 2001.
61. th Congress of the European Academy of Dermatology and Venereology, October 11-15, 2000, Geneva, Switzerland.
62. th Annual Meeting of the American Academy of Dermatology, March 2-7, 2001, Washington DC.
63. T Werfel, A Kapp. What do we know about the etiopathology of the intrinsic type of atopic dermatitis. In: B Wüthrich, ed. The Atopy Syndrome in the Third Millennium. Basel: Karger, 1999, pp. 29-36.
64. Ö Strannegård, I-L Strannegård. Changes in cell-mediated immunity in atopic eczema. In: T Ruzicka, J Ring, B Przybilla, eds. Handbook of Atopic Eczema. Berlin: Springer-Verlag, 1991, pp. 221-231.
65. CA Akdis, M Akdis, D Simon, B Dibbert, M Weber, S Gratzl, O Kreyden, R Disch, B Wüthrich, K Blaser, H-U Simon. Role of T cells and cytokines in the intrinsic form of atopic dermatitis. In: B WUthrich, ed. The Atopy Syndrome in the Third Millennium. Basel: Karger, 1999, pp. 37-44.
66. PJ Hauk, DYM Leung. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Immunol 107:391, 2001.
67. PJ Hauk, QA Hamid, GP Chrousos, DYM Leung. Induction of corticosteroid insensitivity in human peripheral blood mononuclear cells by microbial superantigens. J Allergy Clin Immunol 105:782-787, 2000.